Medifast stock gets a new Bank of America stake

Published on 10/05/2026 at 23:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medifast stock was last at USD 11.67 on October 5, 2026, while Bank of America disclosed an 87,118-share position. Q2 revenue fell 27.6 percent to USD 76.38 million.

MED, US58470H1014, Illustration mit AI erstellt.

Medifast stock (ISIN US58470H1014) was last at USD 11.67 on the NYSE on October 5, 2026, down 0.51 percent from the prior close. The latest institutional filing showed Bank of America taking a new position, putting the companys weak earnings trend beside fresh ownership activity.

Bank of America takes a stake

According to MarketBeat on October 3, 2026, Bank of America purchased 87,118 Medifast shares during Q2 2026 for USD 924,000, equal to 0.78 percent of the company. The filing also placed institutional ownership at 95.51 percent and insider ownership at 3.70 percent.

The transaction is a concrete ownership signal, but the operating figures remain the central issue for the small-cap weight-management company. Medifast sells health and nutrition products through its OPTAVIA brand and an independent coach network.

Revenue falls despite an EPS beat

For Q2 2026, Medifast reported revenue of USD 76.38 million, down 27.6 percent from the prior-year quarter, while diluted EPS was a loss of USD 0.28. Zacks reported that the quarterly loss was narrower than the USD 0.67 consensus loss and that revenue exceeded the USD 76 million estimate.

The revenue decline came with a productivity offset: average revenue per active earning coach increased 41.0 percent year over year to USD 6,529, according to Zacks. Medifast guided for Q3 2026 revenue of USD 60 million to USD 80 million and a loss per share of USD 0.15 to USD 0.65, while retaining its full-year revenue outlook of USD 270 million to USD 300 million.

Analyst target sits above the stock

MarketBeat reported on October 3, 2026, that three analysts give Medifast an average Reduce rating and a USD 12.00 consensus price target. The target lies 2.8 percent above the USD 11.67 share price, a narrow gap that leaves the earnings recovery plan central to the valuation discussion.

Market value and trading range

Medifast was last at USD 11.67 on the NYSE on October 5, 2026 at 4:00 p.m. ET, with a market capitalization of USD 129.8 million and a 52-week range of USD 9.22 to USD 14.15.